Also found in: Wikipedia.
Pregnancy Category: X
As a component of infertility regimens (with recombinant follicle stimulating hormone [FSH], and human chorionic gonadotropin) to inhibit premature luteinizing hormone (LH) surges in patients undergoing controlled ovarian hyperstimulation.
Induces a rapid, reversible suppression of gonadotropin (FSH and LH) secretion, which suppresses surges in LH. Ganirelix is a gonadotropin-releasing hormone antagonist.
Suppression of LH surges increases the implantation and pregnancy rates in patients undergoing in vitro fertilization.
Absorption: Well absorbed following subcutaneous administration.
Distribution: 44 L.
Metabolism and Excretion: Metabolized to two primary metabolites; 18% excreted unchanged in urine.
Half-life: 16 hr.
Time/action profile (blood levels)
Contraindicated in: Hypersensitivity to ganirelix, gonadotropin releasing hormone or any of its analogs; Obstetric: Known or suspected pregnancy.
Use Cautiously in: None noted.
Adverse Reactions/Side Effects
- ovarian hyperstimulation syndrome (life-threatening)
- abdominal pain
- pelvic pain
- vaginal bleeding
- hypersensitivity reactions (life-threatening)
- injection site reactions
Subcutaneous (Adults) 250 mcg once daily during the mid-to-late follicular phase of menstrual cycle after initiating FSH on day 2 or 3 of cycle. Treatment with ganirelix should be continue daily until day of administration of human chorionic gonadotropin (when adequate follicular response achieved).
Injection: 250 mcg/0.5 mL in prefilled syringes
- Assess patient for pregnancy prior to therapy. Therapy should not be initiated if patient is pregnant.
- Lab Test Considerations: May cause elevated neutrophil counts and decreased hematocrit and total bilirubin concentrations.
Potential Nursing DiagnosesDeficient knowledge, related to medication regimen (Patient/Family Teaching)
- Subcutaneous: Administer via subcutaneous injection only.
- Instruct patient on correct technique for subcutaneous injection. Most convenient sites are in the abdomen around the navel and in the upper thigh.
- Successful in vitro fertilization procedure.
ganirelix/gan·i·re·lix/ (gan″ĭ-rel´iks) a synthetic decapeptide derived from, and an antagonist to, gonadotropin-releasing hormone; used as the acetate salt in the treatment of female infertility.
a gonadotropin-releasing hormone antagonist.
indications It is used to inhibit premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation.
contraindications Pregnancy, lactation, latex allergy, and known hypersensitivity to this drug prohibit its use.
adverse effects Fetal death is a life-threatening consequence of this drug's use. Other adverse effects include headache, ovarian hyperstimulation syndrome, gynecological abdominal pain, nausea, and pain on injection. Common side effects include spotting and breakthrough bleeding.